Idenix Pharmaceuticals Inc (IDIX)

24.50
0.05 0.20
Prev Close 24.45
Open 24.49
Day Low/High 24.46 / 24.50
52 Wk Low/High 2.93 / 24.50
Volume 5.09M
Avg Volume 2.96M
Exchange
Shares Outstanding 151.50M
Market Cap 3.71B
EPS -0.91
Div & Yield N.A. (N.A)
Idenix Hep C Fortunes Fade Fast

Idenix Hep C Fortunes Fade Fast

It was only 9 months ago that Idenix was riding high on takeout speculation. Today, not so much.

Idenix Provides Update On IDX19368 Development Program

Idenix Provides Update On IDX19368 Development Program

IDX19368, for Which Idenix Has Submitted an IND Application, Has Been Placed on Clinical Hold by FDA

Idenix Pharmaceuticals' CEO Provides Update On IDX184 Clinical Development Program Conference (Transcript)

Idenix Pharmaceuticals' CEO Provides Update On IDX184 Clinical Development Program Conference (Transcript)

Idenix Pharmaceuticals' CEO Provides Update on IDX184 Clinical Development Program Conference (Transcript)

Stocks Rise on Housing Report, Cisco Surge

Stocks Rise on Housing Report, Cisco Surge

The S&P 500 comes within 5 points of its high for the past year.

3 Hot Stocks to Trade (or Not)

3 Hot Stocks to Trade (or Not)

Here's a look at how to trade some of today's most active stocks.

Idenix Pharmaceuticals Reports Second Quarter And Six Month 2012 Financial Results And HCV Program Update

Idenix Pharmaceuticals Reports Second Quarter And Six Month 2012 Financial Results And HCV Program Update

Company Will Have Three HCV Clinical Programs by End of Third Quarter

Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up

Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up

The two Hep C drugs are similar enough chemically to warrant caution.

Biotech Stock Mailbag: Mela, Osiris, Talon

Biotech Stock Mailbag: Mela, Osiris, Talon

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Bristol's Hep C Drug Blow Up May Benefit Gilead, Idenix, Vertex Pharma

Bristol's Hep C Drug Blow Up May Benefit Gilead, Idenix, Vertex Pharma

Bristol suspends a promising Hep C drug due to heart failure.

UBS Posts Worse-than-Expected Q2 Profit: Hot Trends

UBS Posts Worse-than-Expected Q2 Profit: Hot Trends

A look at the day's most searched trends on the Web, including UBS after the Swiss bank posted a worse-than-expected second-quarter profit due to losses it incurred from the Facebook initial public offering.

UBS Posts Worse-than-Expected Profit: Hot Trends

UBS Posts Worse-than-Expected Profit: Hot Trends

UBS posts a worse-than-expected second-quarter profit due to losses it incurred from the Facebook initial public offering.

4 Stocks Under $10 Ripping Higher

4 Stocks Under $10 Ripping Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Earnings Season Begins

Estimates for S&P 500 companies have come down in the last month, but they might not be low enough.

7 Stocks Soaring on Monster Volume

7 Stocks Soaring on Monster Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Bulls Take Another Shot on Idenix

Bulls Take Another Shot on Idenix

Idenix Pharmaceuticals didn't perform after a bullish trade last month, but investors are trying again.

5 Stocks Under $10 Poised for Breakouts

5 Stocks Under $10 Poised for Breakouts

These under-$10 stocks look poised to trade higher from current levels.

7 Stocks Under $10 Spiking Higher

7 Stocks Under $10 Spiking Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Idenix Pharmaceuticals' CEO Presents At Deutsche Bank 37th Annual Healthcare Conference (Transcript)

Idenix Pharmaceuticals' CEO Presents At Deutsche Bank 37th Annual Healthcare Conference (Transcript)

Idenix Pharmaceuticals' CEO Presents at Deutsche Bank 37th Annual Healthcare Conference (Transcript)

Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix

Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix

A closer look at Bristol-Myers Squibb's hepatitis C drug BMS-094 raises troubling questions.

Vertex Hopes Two Cystic Fibrosis Drugs Better than One

Vertex Hopes Two Cystic Fibrosis Drugs Better than One

A preview of two clinical trials that will drive Vertex's stock price this summer.

Grading Hep C Stocks Exiting EASL Confab

Grading Hep C Stocks Exiting EASL Confab

Healthcare investor Nathan Sadeghi-Nejad grades the hepatitis C drug stocks following the closely watched EASL conference.

Gilead, Bristol Put Profits Ahead of Best Care for Hep C Patients

Gilead, Bristol Put Profits Ahead of Best Care for Hep C Patients

An exciting new hepatitis C treatment may never reach patients because Bristol-Myers Squibb and Gilead Sciences can't work together.

More Hep C Drug Abstracts Leak Ahead of EASL Confab

More Hep C Drug Abstracts Leak Ahead of EASL Confab

The leaked EASL abstracts include a key study of Gilead Sciences' GS-7977.

Winners, Losers From EASL Hep C Data Dump

Winners, Losers From EASL Hep C Data Dump

Abbott emerges as an early favorite in the race to develop a new therapy for hepatitis C.

EASL Backs Down, Will Publicly Disclose Key Hep C Data

EASL Backs Down, Will Publicly Disclose Key Hep C Data

Reacting to criticism about selective disclosure, EASL alters research abstract distribution policy ahead of its important Hep C meeting.

EASL Can't Even Decide on a Date to Unfairly Disclose Key Hep C Data

EASL Can't Even Decide on a Date to Unfairly Disclose Key Hep C Data

It's amateur hour at EASL as the medical society can't decide on a date to selectively disclose research abstracts for its meeting next month.

EASL Gives Wall Street's Privileged Investors Sneaky Preview to Key Hep C Data

EASL Gives Wall Street's Privileged Investors Sneaky Preview to Key Hep C Data

You thought investing in Hep C stocks ahead of a key European conference is fair? Guess again, thanks to EASL and its selective disclosure policy.

For Biotech, 'Fail' is Making a Big Comeback

For Biotech, 'Fail' is Making a Big Comeback

A series of disappointments and setbacks is cooling off the once red-hot biotech sector.